Accessibility Statement Skip Navigation
  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing
  • Login
  • GDPR
  • Create a Free Account
Return to PRWeb homepage
  • News
  • Resources
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
  • Business & Money
      • Auto & Transportation

      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Hamburger menu
  • Cision PRWeb provides efficient communication tools to continuously engage with target audiences across multiple online channels
  • Create a Free Account
    • ALL CONTACT INFO
    • Contact Us


      11AM ET Sunday – 8PM ET Friday

  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR

NGS Accreditation with ASHI Standards at the ASHI Annual Meeting 2016
  • USA - English


News provided by

Omixon Biocomputing

Sep 23, 2016, 09:00 ET

Share this article

Share toX

Share this article

Share toX

Tim Hague, CEO, Omixon
Tim Hague, CEO, Omixon

HLA typings for solid organ make up the majority of all clinical typings around the world, and we are delighted to see how many labs are recognizing that NGS is a technology that can replace their SSO/SSP workflows, and not just their SBT workflows

Post this

Budapest, Hungary & Cambridge, MA (PRWEB) September 23, 2016 -- Global molecular diagnostics company Omixon, headquartered in Budapest with US offices in Cambridge, MA, announce today that Holotype HLA™ and other Omixon products will be featured in four oral presentations and five poster presentations produced by customers or collaborators at the annual meeting of the American Society for Histocompatibility and Immunogenetics (ASHI) in St Louis, MO. Additionally, Omixon’s Lunch Symposium on Thursday will focus on the ASHI accreditation process for NGS (see a summary of Omixon’s activities below).

Among the oral presentations, Dr. Peter Meintjes, Omixon’s CCO, will present “The Economics of NGS” to highlight how the costs of NGS scale with volume and the number of loci, and how NGS compares to legacy technologies as a suitable replacement for labs with any throughput. The more research-heavy oral presentations will feature Dr. Jamie Duke of The Children’s Hospital of Philadelphia (CHOP) whose topic “Detecting low level clonal somatic mutation in HLA genes using next-generation sequencing in the presence of aplastic anemia” highlights complex cases of challenging samples in which Holotype HLA is superior in its ability to detect low frequency signals in chimeric samples. A third oral presentation by Eszter Lazar-Molnar from ARUP Laboratories tackles a similar issue of detecting low frequency signals due to loss of heterozygosity in her presentation entitled “Resolution of conflicting HLA assignment due to loss of heterozygosity in the HLA region by NGS typing”.

Accreditation and validation will be the major topic of Omixon’s Lunch Symposium, featuring three independent speakers, who will also speak about their experience in working with Omixon. Two HLA lab Directors that have made leading contributions to the ASHI NGS validation/accreditation standards, Dr. Zahra Kashi and Dr. Lee Ann Baxter Lowe will provide their views, as well as Doreen Sese from Yale University – the first lab in the world to become ASHI accredited with NGS for serving only solid organ programs, moving directly from SSO/SSP workflows to NGS without accrediting SBT, acting as a pioneer for other solid organ only labs.

The case for high resolution typing by NGS for solid organ transplantation will be further enhanced by Yanping Huang of CHOP in her oral presentation entitled “Three case reports: NGS-based high resolution HLA typing permits better assessment of donor-recipient compatibility in solid organ transplant”. Her presentation is expected to provide a significant stimulus for more solid organ labs to adopt NGS typing for HLA. Omixon’s CEO, Tim Hague, notes that “HLA typings for solid organ make up the majority of all clinical typings around the world, and we are delighted to see how many labs are recognizing that NGS is a technology that can replace their SSO/SSP workflows, and not just their SBT workflows”.

Tim Hague and Dr. Peter Meintjes will be supported at the event by a six-strong team including Head of Lab and Field Operations, Efi Melista, Market Development Manager, Nora Nagy, and Sales Directors Faisal Mojaddidi and Maggi Woronkowicz, CHS. Dr. Meintjes notes that “The ASHI meeting is an unparalleled opportunity to share in the latest trends through the formal program, informal networking and one-on-one consultative sessions with Omixon”. Rounding out the scientific program for Omixon will be the second convening of Omixon’s Scientific Advisory Board (SAB), Chaired by Professor Dimitri Monos, with contributing SAB Members Prof. Malek Kamoun, Prof. Dominique Charron and Dr. Matthew Anderson.

Omixon at ASHI 2016
Sept. 26-30 | Omixon will be exhibiting at Booth #415 throughout the conference
Sept. 26, 9.30 - 11:00am | Workshop - Introduction to NGS-based HLA Typing (Register here)
Sept. 26, 11:30am - 1pm | Workshop - Resolving Complex Cases of NGS-based HLA Typing (Register here)
Sept. 29, 12:30 - 2:20pm | ASHI 2016 Symposium - NGS Accreditation with ASHI Standards (Register here)

Omixon featured in Oral Presentations
OR31 | P Meintjes et al. (2016) - The economics of next generation sequencing, at 3:30pm on Wed 9/28
OR46 | JL Duke et al. (2016) - Detecting low level clonal somatic mutation in HLA genes using next-generation sequencing in the presence of aplastic anemia, at 4pm on Thurs 9/29
OR48 | E Lazar-Molnar et al. (2016) - Resolution of conflicting HLA assignment due to loss of heterozygosity in the HLA region by NGS typing, at 4:15pm on Wed 9/28
OR53 | Y Huang et al. (2016) - Three case reports: NGS-based high resolution HLA typing permits better assessment of donor-recipient compatibility in solid organ transplant, at 4:15pm on Wed 9/28

Omixon featured in Poster Presentations
P017 | R Pollok (2016) - Automation of HLA-typing using next generation sequencing with Omixon's holotype HLA X2 kit and beckman-coulter's biomek liquid handling system
P056 | CL Saw et al. (2016) - Simultaneous HLA class I and II sequencing by long read-independent circular consensus SMRT technology
P090 | R Ameen et al. (2016) - NGS characterization of HLA haplotypes in multi-generation families of Kuwaiti descent
P091 | T. Profaizer et al. (2016) - Comparison of four HLA next-generation sequencing typing methods
P135 | M Schäfer et al. (2016) - Determination of the whole HLA-DQB1∗ 06: 37 sequence by the combination of long range polymerase chain reaction, next generation sequencing and phasing

About Omixon
Omixon is a global molecular diagnostics company, headquartered in Budapest, Hungary, with US offices in Cambridge, MA that commercializes disruptive technologies for clinical and research laboratories. Omixon’s flagship product, Holotype HLA™, is the world’s leading NGS-based HLA genotyping product that delivers the most accurate high-resolution HLA genotyping available, and is used in more than 20 hospitals worldwide. Omixon’s research software, HLA Explore™ analyzes data from any sequencing technology and determines HLA genotypes from Whole Exome/Genome Sequencing experiments. Omixon maintains an active grant-funded research program with a product pipeline focused on pre- and post-transplantation, and HLA genotyping applications beyond transplantation. For more information, visit the Omixon website.

Peter Meintjes, PhD, Omixon Biocomputing, http://www.omixon.com, +1 2039472772, [email protected]

Modal title

Contact PRWeb

  • 11AM ET Sunday – 8PM ET Friday
  • Contact Us

About PRWeb

  • About PRWeb
  • Partners
  • Partnership Programs
  • Editorial Guidelines
  • Resources

Why PRWeb

  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing

Accounts

  • Create a Free Account
  • Log in
  • Contact Us

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact Cision

Products

About

My Services
  • All News Releases
  • Online Member Center
  • ProfNet
Cision Distribution Helpline
888-776-0942
  • Legal
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 Cision US Inc.